SEC 13F Intelligence

Paragon Associates & Paragon Associates II Joint Venture / DMAC

Paragon Associates & Paragon Associates II Joint Venture’s Diamedica Therapeutics Inc Position

Does Paragon Associates & Paragon Associates II Joint Venture own Diamedica Therapeutics Inc (DMAC)? Yes — 875.0K shares worth $6M (+8.05% of its 13F portfolio) as of Q1 2026.

Position Value
$6M
Q1 2026
Shares
875.0K
% of Portfolio
+8.05%
Quarters Held
12
currently held

Position History DMAC

Reported value by quarter
Q2 ’23: $1MQ2 ’23Q3 ’23: $1MQ4 ’23: $1MQ4 ’23Q1 ’24: $1MQ2 ’24: $1MQ2 ’24Q3 ’24: $2MQ4 ’24: $3MQ4 ’24Q1 ’25: $2MQ2 ’25: $3MQ2 ’25Q3 ’25: $6MQ4 ’25: $7MQ4 ’25Q1 ’26: $6Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026875.0K$6M+8.05%
Q4 2025875.0K$7M+14.39%
Q3 2025875.0K$6M+10.72%
Q2 2025650.0K$3M+4.03%
Q1 2025600.0K$2M+5.33%
Q4 2024514.8K$3M+6.46%
Q3 2024482.6K$2M+3.63%
Q2 2024482.6K$1M+3.48%
Q1 2024500.0K$1M+2.47%
Q4 2023500.0K$1M+3.26%
Q3 2023470.0K$1M+3.97%
Q2 2023325.0K$1M+2.87%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Paragon Associates & Paragon Associates II Joint Venture’s full portfolio or all institutional holders of DMAC.